Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$283.82-1.1%$261.72$122.80▼$303.00$8.36B0.5292,078 shs296,143 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-2.46%+1.95%-4.84%+60.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$283.82-1.1%$261.72$122.80▼$303.00$8.36B0.5292,078 shs296,143 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-2.46%+1.95%-4.84%+60.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.83Moderate Buy$324.1114.20% UpsideCurrent Analyst Ratings BreakdownLatest KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/9/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)3/27/2026KRYSKrystal Biotech Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/25/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)2/25/2026KRYSKrystal Biotech GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$224.00 ➝ $284.002/18/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)2/18/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$336.00 ➝ $371.002/18/2026KRYSKrystal Biotech Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$220.00 ➝ $323.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$389.13M21.47$7.78 per share36.50$42.06 per share6.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$204.83M$6.8541.4425.83N/A52.64%18.69%17.12%N/ALatest KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.959.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21029.44 million25.58 millionOptionableKRYS HeadlinesRecent News About These CompaniesKrystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results1 hour ago | benzinga.comKrystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus1 hour ago | zacks.comA Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum3 hours ago | finance.yahoo.comKrystal Biotech (NASDAQ:KRYS) Sets New 52-Week High After Better-Than-Expected Earnings4 hours ago | marketbeat.comQ2 EPS Estimates for Krystal Biotech Raised by HC WainwrightMay 5 at 8:32 AM | marketbeat.comKrystal Biotech posts strong Q1, eyes 6 data readouts in 2026May 5 at 1:16 AM | msn.comKrystal Biotech, Inc. Q1 2026 Earnings Call SummaryMay 5 at 1:16 AM | finance.yahoo.comKrystal Biotech Earnings Call Highlights Profitable GrowthMay 4 at 8:31 PM | tipranks.comKrystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call TranscriptMay 4 at 2:07 PM | seekingalpha.comHC Wainwright Reiterates "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)May 4 at 1:03 PM | marketbeat.comKrystal Biotech Q1 Earnings Call HighlightsMay 4 at 10:37 AM | marketbeat.comKrystal Biotech stock rises over 6% on earnings beat and strong revenueMay 4 at 10:14 AM | za.investing.comKrystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue EstimatesMay 4 at 9:15 AM | zacks.comVanguard Group Inc. Trims Stock Position in Krystal Biotech, Inc. $KRYSMay 4 at 7:56 AM | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPSMay 4 at 7:30 AM | marketbeat.comKrystal Biotech Announces First Quarter 2026 Financial and Operating ResultsMay 4 at 7:00 AM | globenewswire.comKrystal Biotech (KRYS) Expected to Announce Quarterly Earnings on MondayMay 3 at 4:31 AM | americanbankingnews.comHow The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage PipelineMay 2 at 12:54 AM | finance.yahoo.comKymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2026 | zacks.comKrystal Biotech to Present at Upcoming Scientific ConferencesApril 30, 2026 | globenewswire.comPictet Asset Management Holding SA Sells 40,336 Shares of Krystal Biotech, Inc. $KRYSApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRYS Company DescriptionsKrystal Biotech NASDAQ:KRYS$283.82 -3.13 (-1.09%) As of 03:55 PM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
